Serum Institute of India (SII) has started ‘at-risk’ production of Covovax vaccine, two persons aware of the development said, expecting regulators to grant emergency licence for the promising protein subunit vaccine. “They have started producing Covovax at risk on a small scale using some raw materials it had. SII will also be scaling up its Covishield capacity to provide around 90 million doses in June and will increase it further to provide around 100 million doses or more in July, the person said. So far, the company was manufacturing around 60-70 million doses a month. Currently, SII is servicing an order of 110 million doses worth ₹1,732.50 crore that has to be supplied by July.

Source: Mint May 31, 2021 18:33 UTC